Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 13/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19630615 | 0.90 | APP (0.75) | APPCYP1A2F2RL3NPC1RAB9A | |
| SCHEMBL10167864 | 0.87 | APP (1.00) | APPCYP1A2NPC1RAB9AMAOB | |
| SCHEMBL563335 | 0.84 | APP (0.79) | APPCYP1A2NPC1RAB9AMAOB | |
| SCHEMBL29809000 | 0.84 | APP (0.79) | APPCYP1A2NPC1RAB9AMAOB | |
| SCHEMBL23623803 | 0.80 | APP (0.78) | APPCYP1A2NPC1RAB9AMAOB | |
| SCHEMBL19627047 | 0.80 | APP (0.70) | APPCYP1A2F2RL3 | |
| SCHEMBL19627050 | 0.79 | APP (0.78) | APPCYP1A2F2RL3MAOBACHE | |
| SCHEMBL1104921 | 0.78 | APP (1.00) | APPCYP1A2F2RL3NPC1RAB9A | |
| SCHEMBL10167879 | 0.78 | APP (0.80) | APPCYP1A2NPC1RAB9AMAOB | |
| SCHEMBL18467806 | 0.78 | APP (0.80) | APPCYP1A2NPC1RAB9AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334865-A1 | DDR2 INHIBITORS AND METHODS OF USING | WASHINGTON UNIVERSITY (US) | 2017-11-23 | — | — | US | disclosed |
| US-20170334865-A1 | DDR2 INHIBITORS AND METHODS OF USING | WASHINGTON UNIVERSITY (US) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334865-A1 | DDR2 INHIBITORS AND METHODS OF USING | DDR2, DDR1, DDRGK1 | APP 3057/4885CYP1A2 4799/4885F2RL3 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.